In this study, the bLP-mediated TECA strategy remarkably improve second nanoparticles accessibility to cancer cells or even CSCs in tumor, providing an encouraging approach to treat tumor relapse and metastasis. The gene discussed is DYNLRB1; the disease is cancer.